AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8044944 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 301
Study 8044944 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 301
Study 2960296 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion (0.3 mg/kg/d continuous floxuridine infusion, alternating with saline solution every two weeks)
Number of subjects: 25
Study 2960296 — intervention group
Group type: COMPARATOR
Intervention: Portal vein infusion (0.3 mg/kg/d continuous floxuridine infusion, alternating with saline solution every two weeks)
Number of subjects: 25
Study 2960296 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to hepatic arterial infusion after portal vein infusion
Number of subjects: 25
Study 31715641 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-containing mouth rinse
Number of subjects: 164
Study 31715641 — intervention group
Group type: EXPERIMENTAL
Intervention: Xerostomia Inventory (XI)
Number of subjects: 164
Study 31715641 — intervention group
Group type: EXPERIMENTAL
Intervention: Summated Xerostomia Inventory (SXI)
Number of subjects: 164
Study 29255900 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 410
Study 29255900 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 300 mg
Number of subjects: 410
Study 29255900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 27352414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-staffed gout management program
Number of subjects: 77
Study 27352414 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 77
Study 24708338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel technique with subepithelial connective tissue graft (TUN)
Number of subjects: 24
Study 24708338 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap with enamel matrix derivative (CAF)
Number of subjects: 24
Study 23685914 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with releasable sutures
Number of subjects: 176
Study 23685914 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy without releasable sutures
Number of subjects: 176
Study 21569996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination-therapy trastuzumab plus docetaxel (H+D)
Number of subjects: 101
Study 21569996 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy of single-agent trastuzumab followed by docetaxel (H→D)
Number of subjects: 101
Study 21569996 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy trastuzumab in H→D group
Number of subjects: 101
Study 21569996 — intervention group
Group type: COMPARATOR
Intervention: Subsequent docetaxel in H→D group
Number of subjects: 101
Study 21569996 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective analysis of trastuzumab treatment beyond progression
Number of subjects: 101
Study 19485821 — intervention group
Group type: EXPERIMENTAL
Intervention: BPBM/GTR/PRP (experimental group)
Number of subjects: 23
Study 19485821 — intervention group
Group type: COMPARATOR
Intervention: BPBM/GTR (control group)
Number of subjects: 23
Study 17049693 — intervention group
Group type: EXPERIMENTAL
Intervention: Leishmanization (LZ) with alum-precipitated autoclaved Leishmania major and BCG
Number of subjects: 0
Study 17049693 — intervention group
Group type: EXPERIMENTAL
Intervention: Leishmanization (LZ)
Number of subjects: 0
Study 12771518 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5‐fluorouracil (AV‐CMF)
Number of subjects: 263
Study 12771518 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF)
Number of subjects: 263
Study 11057795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine at 0.5 microg/kg/min
Number of subjects: 412
Study 11057795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine at 2.0 microg/kg/min
Number of subjects: 412
Study 11057795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 11057795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (both doses)
Number of subjects: 412
Study 9299913 — intervention group
Group type: EXPERIMENTAL
Intervention: Single question repeated 12 times
Number of subjects: 0
Study 9299913 — intervention group
Group type: EXPERIMENTAL
Intervention: Four different questions repeated 3 times
Number of subjects: 0
Study 9299913 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulating information across repetitions and physiological measures
Number of subjects: 0
Study 9299913 — intervention group
Group type: EXPERIMENTAL
Intervention: High motivation
Number of subjects: 0
Study 9299913 — intervention group
Group type: EXPERIMENTAL
Intervention: Low motivation
Number of subjects: 0
Study 8399607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal vancomycin (1 g) and oral pefloxacin (400 mg b.i.d.)
Number of subjects: 60
Study 8399607 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal vancomycin (1 g) and gentamicin (80 mg loading dose, followed by 15 mg/2 L)
Number of subjects: 60
Study 6576742 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet aerosol salbutamol (10 mg, 4 x 0.5 ml of 0.5% standard solution)
Number of subjects: 20
Study 6576742 — intervention group
Group type: COMPARATOR
Intervention: Metered dose inhaler (MDI) salbutamol (800 micrograms, 8 x 100 micrograms)
Number of subjects: 20
Study 31104629 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive of 2.00 for every maternal client attending postnatal care within 48 h of delivery (treatment group)
Number of subjects: 207
Study 31104629 — intervention group
Group type: COMPARATOR
Intervention: No monetary incentive (control group)
Number of subjects: 207
Study 31104629 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive of 2.00 for every neonatal client attending postnatal care within 48 h of delivery (treatment group)
Number of subjects: 207
Study 29348651 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 75 mg
Number of subjects: 63
Study 29348651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 27109132 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest bathing trip
Number of subjects: 0
Study 27109132 — intervention group
Group type: COMPARATOR
Intervention: Urban area (control)
Number of subjects: 0
Study 24441968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecstasy users (n=18)
Number of subjects: 45
Study 24441968 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=21)
Number of subjects: 45
Study 22748591 — intervention group
Group type: EXPERIMENTAL
Intervention: EVG/COBI/FTC/TDF
Number of subjects: 700
Study 22748591 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 700
Study 20554464 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 98
Study 20554464 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 98
Study 18070468 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d and aspirin 100 mg/d plus cilostazol 200 mg/d
Number of subjects: 402
Study 18070468 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d and aspirin 100 mg/d
Number of subjects: 402
Study 16683408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily
Number of subjects: 94
Study 16683408 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tibolone)
Number of subjects: 94
Study 14738775 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected outcomes of operations (1 object + 1 tone = 2 objects and 1 object + 2 tones = 3 objects)
Number of subjects: 0
Study 14738775 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected outcomes of operations (1 object + 2 tones = 2 objects and 1 object + 1 tone = 3 objects)
Number of subjects: 0
Study 10988282 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily)
Number of subjects: 216
Study 10988282 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily for 1 week, then 50 mg twice daily for 5 weeks)
Number of subjects: 216
Study 10988282 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg daily) with Losartan
Number of subjects: 216
Study 10988282 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg daily) with Captopril
Number of subjects: 216
Study 10988282 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (with Indomethacin)
Number of subjects: 216
Study 10988282 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (with Indomethacin)
Number of subjects: 216
Study 8989058 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia (subcutaneous anesthetic infiltration)
Number of subjects: 270
Study 8989058 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 270
Study 8989058 — intervention group
Group type: COMPARATOR
Intervention: Venous puncture
Number of subjects: 270
Study 1503330 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 101
Study 1503330 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 101
Study 6739139 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalcillin 500 mg
Number of subjects: 26
Study 6739139 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalcillin 1000 mg
Number of subjects: 26
Study 6739139 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalcillin 2000 mg
Number of subjects: 26
Study 6739139 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalcillin 3000 mg
Number of subjects: 26
Study 6739139 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalcillin (all doses)
Number of subjects: 26
Study 31721275 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaf and Hard-of-Hearing college students
Number of subjects: 12056
Study 31721275 — intervention group
Group type: COMPARATOR
Intervention: Hearing college students
Number of subjects: 12056
Study 31317029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene 7 mg daily
Number of subjects: 30
Study 31317029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene 30 mg daily (formulation 1)
Number of subjects: 30
Study 31317029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene 30 mg daily (formulation 2)
Number of subjects: 30
Study 31317029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC) with 7 mg lycopene
Number of subjects: 30
Study 31317029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC)
Number of subjects: 30
Study 28011328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 0
Study 28011328 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + complex electrogram
Number of subjects: 0
Study 28011328 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + linear ablation
Number of subjects: 0
Study 28011328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rhythm (SR)
Number of subjects: 0
Study 28011328 — intervention group
Group type: EXPERIMENTAL
Intervention: AF termination
Number of subjects: 0
Study 28011328 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolongation of AF cycle length (AFCL)
Number of subjects: 0
Study 26140823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) for SAD
Number of subjects: 86
Study 23223345 — intervention group
Group type: EXPERIMENTAL
Intervention: UNSAT diet (unsaturated fat-rich diet)
Number of subjects: 164
Study 23223345 — intervention group
Group type: COMPARATOR
Intervention: CARB diet (carbohydrate-rich diet)
Number of subjects: 164
Study 23223345 — intervention group
Group type: COMPARATOR
Intervention: PROT diet (protein-rich diet)
Number of subjects: 164
Study 21850574 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide 300 mg administered once daily under fasting conditions
Number of subjects: 20
Study 21850574 — intervention group
Group type: COMPARATOR
Intervention: Tyramine 200 mg administered alone
Number of subjects: 20
Study 21850574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine 50 mg and 100 mg administered on days 5, 6, and 7 respectively
Number of subjects: 20
Study 20015429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel thread‐drawing method
Number of subjects: 244
Study 20015429 — intervention group
Group type: COMPARATOR
Intervention: Classical therapy of thread‐drawing method (control)
Number of subjects: 244
Study 16709702 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous noise combined with impulse noise
Number of subjects: 1804
Study 16709702 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift work
Number of subjects: 1804
Study 16709702 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical workload
Number of subjects: 1804
Study 16709702 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to two risk factors
Number of subjects: 1804
Study 16709702 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to all three risk factors
Number of subjects: 1804
Study 12857474 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 47
Study 12857474 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE) + Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 47
Study 12857474 — intervention group
Group type: COMPARATOR
Intervention: Basic Treatment
Number of subjects: 47
Study 10960753 — intervention group
Group type: EXPERIMENTAL
Intervention: 36% phosphoric acid
Number of subjects: 30
Study 10960753 — intervention group
Group type: EXPERIMENTAL
Intervention: non-rinse conditioner (NRC, Dentsply DeTrey)
Number of subjects: 30
Study 10960753 — intervention group
Group type: COMPARATOR
Intervention: no conditioning
Number of subjects: 30
Study 8969720 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator (Breathe Right Nasal Strips)
Number of subjects: 20
Study 1451897 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine activity monitoring with findings revealed to clinicians (study group, n=9)
Number of subjects: 58
Study 1451897 — intervention group
Group type: COMPARATOR
Intervention: Uterine activity monitoring with findings not revealed to clinicians (control group, n=10)
Number of subjects: 58
Study 6748924 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate loading
Number of subjects: 10
Study 6748924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30650322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (300 mg single dose)
Number of subjects: 522
Study 30650322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 522
Study 30650322 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (15 mg once daily for 14 days)
Number of subjects: 522
Study 30304106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 355
Study 30304106 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin 5 mg
Number of subjects: 355
Study 26935578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide (2000 mg IV twice weekly) with metronomic temozolomide (60 mg/m²) and procarbazine (50 or 100 mg)
Number of subjects: 29
Study 25044247 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on approximate arithmetic
Number of subjects: 0
Study 25044247 — intervention group
Group type: COMPARATOR
Intervention: Numerical comparison
Number of subjects: 0
Study 25044247 — intervention group
Group type: COMPARATOR
Intervention: Numerical matching
Number of subjects: 0
Study 25044247 — intervention group
Group type: COMPARATOR
Intervention: Visuo-spatial short-term memory
Number of subjects: 0
Study 22853980 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m(2)) plus Ramucirumab (10 mg/kg)
Number of subjects: 1242
Study 22853980 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m(2)) plus Placebo
Number of subjects: 1242
Study 19853947 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 11618
Study 17409312 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta, 1 mg/kg biweekly for up to 54 months
Number of subjects: 58
Study 15365746 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (24 probands)
Number of subjects: 48
Study 15365746 — intervention group
Group type: COMPARATOR
Intervention: Group B (24 probands)
Number of subjects: 48
Study 11232671 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation (18-mm through-the-scope balloon)
Number of subjects: 83
Study 11232671 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 83
Study 9756423 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler method for brachial systolic blood pressure measurement
Number of subjects: 50
Study 9756423 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultatory method for brachial systolic blood pressure measurement
Number of subjects: 50
Study 9756423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillometric method for brachial systolic blood pressure measurement
Number of subjects: 50
Study 8091825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine with simultaneous volume loading (by CVP)
Number of subjects: 0
Study 8091825 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamines (dobutamine and adrenaline)
Number of subjects: 0
Study 3421071 — intervention group
Group type: EXPERIMENTAL
Intervention: Rydell four-flanged hook nail
Number of subjects: 223
Study 3421071 — intervention group
Group type: COMPARATOR
Intervention: Gouffon pins
Number of subjects: 223
Study 29649631 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial behavioral and medication management intervention delivered via telephone, including up to 36 monthly educational modules, home blood pressure monitoring, and electronic medication management recommendations.
Number of subjects: 281
Study 29649631 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 281
Study 28128646 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 40
Study 28128646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Number of subjects: 40
Study 26516434 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Cyclogest)
Number of subjects: 78
Study 26516434 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone (17‐α hydroxyprogesterone caproate)
Number of subjects: 78
Study 26516434 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 78
Study 24081245 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (prednisone, azathioprine, N-acetylcysteine)
Number of subjects: 1
Study 24081245 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 1
Study 24081245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 20851818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous mononuclear bone marrow cells (mBMCs)
Number of subjects: 100
Study 20851818 — intervention group
Group type: COMPARATOR
Intervention: Control (no mBMCs)
Number of subjects: 100
Study 18310647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored messages to prepare families for withdrawal of life support
Number of subjects: 20
Study 18310647 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 16503543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil intravenous analgesia (1 microg/ml)
Number of subjects: 60
Study 16503543 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl intravenous analgesia (10 microg/ml)
Number of subjects: 60
Study 14623813 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 468
Study 10638374 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity dynamic resistance training (WT)
Number of subjects: 37
Study 10638374 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 9480650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (800 mg daily for 7-10 days)
Number of subjects: 30
Study 9480650 — intervention group
Group type: COMPARATOR
Intervention: Routine antibiotics (benzylpenicillin, ampicillin, erythromycin)
Number of subjects: 30
Study 8438774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose maldigesters and intolerant group
Number of subjects: 164
Study 8438774 — intervention group
Group type: COMPARATOR
Intervention: Low-lactose milk and milk containing lactose
Number of subjects: 164
Study 3679106 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive art therapy group (10 weeks)
Number of subjects: 100
Study 3679106 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 30288918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (PSA tests and digital rectal examinations)
Number of subjects: 76383
Study 30288918 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 76383
Study 30288918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 76383
Study 30288918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 76383
Study 27824737 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone‐iodine
Number of subjects: 122
Study 27824737 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine gluconate
Number of subjects: 122
Study 27824737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 122
Study 25880054 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day omega‐3 fatty acids plus 400 IU/day vitamin E (OE)
Number of subjects: 67
Study 25880054 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day omega‐3 fatty acids plus vitamin E placebo (OP)
Number of subjects: 67
Study 25880054 — intervention group
Group type: COMPARATOR
Intervention: Both omega‐3 fatty acid and vitamin E placebos (PP)
Number of subjects: 67
Study 23907314 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial approach
Number of subjects: 86
Study 23907314 — intervention group
Group type: COMPARATOR
Intervention: Subplatysmal approach
Number of subjects: 86
Study 21497319 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week supervised hip flexor stretching program (twice-daily, supervised twice weekly)
Number of subjects: 74
Study 21497319 — intervention group
Group type: COMPARATOR
Intervention: Shoulder abductor stretching program (control group)
Number of subjects: 74